May 20, 2013 – Although relationships between the pharmaceutical industry and physicians have come under greater scrutiny as the implementation ... read more
May 16, 2013 – The Centers for Medicare & Medicaid Services (CMS) is likely “to find itself the target of ... read more
May 14, 2013 — In a Medical Marketing and Media (MMM) column posted May 1, Coalition for Healthcare Communication Executive ... read more
May 6, 2013 — With Sunshine Act reporting slated to begin in less than three months, it is sobering to ... read more
April 29, 2013 – Although the Digital Advertising Alliance (DAA) has made great strides to protect consumers’ privacy online – ... read more
April 22, 2013 – In April 18 comments to the Centers for Medicare & Medicaid Services (CMS) the Coalition for ... read more
April 4, 2013 – A new White Paper, “FDA Communications Oversight in a Digital Era,” issued April 2 by Eye ... read more
April 4, 2013 — Headlines run by news outlets regarding the status of industry-physician relationships rarely focus on the benefits ... read more
April 1, 2013 – By John Kamp, Executive Director, Coalition for Healthcare Communication While not directly about communication and marketing, ... read more
March 22, 2013 – Although spending on drug promotion has declined in recent years, 2013 could be a pivotal year ... read more
March 19, 2013 – Although the FDA has not yet issued its long-awaited social media guidance for the biopharma industry, ... read more
March 11, 2013 – Healthcare industry collaborations with physicians and researchers have “been at the heart of most of the ... read more
March 4, 2013 – A recent study released by the National Bureau of Economic Research (NBER) states that although consumer-directed ... read more
Feb. 25, 2013 – The Centers for Medicare & Medicaid (CMS) launched its “OPENPAYMENTS” Website last week, which will be ... read more
On Feb. 1, the Centers for Medicare & Medicaid Services (CMS) issued a final rule implementing the Sunshine Act provisions ... read more
Many Questions Still Unresolved Feb. 4, 2013 – Although the final rule to implement the Sunshine provisions of the Affordable ... read more
Jan. 15, 2013 – If 2012 – with its high number of new drug approvals, senior staff stability within the ... read more
Nov. 27, 2012 – An Oct. 31 enforcement letter from the FDA’s Office of Prescription Drug Promotion (OPDP) to Cornerstone ... read more
Feb. 23, 2012 – At a White House meeting held today to unveil the blueprint for the Obama Administration’s “Consumer ... read more
By John Kamp, Executive Director, Coalition for Healthcare Communication July 18, 2011 — For those who have not read the ... read more
You can visit Pharma Live’s Med Ad News website to download podcasts on healthcare issues by John Kamp, the Coalition’s Executive Director.
The 1st is on the defeated but still looming ad tax bill. The 2nd is an overview and analysis of the “New FDA.”
Med Ad News plans to present 3 more podcasts in this series.
A new study by 4 researchers from the Cleveland Clinic showed that industry support of continuing medical education created no bias among participants.
The study acknowledges the controversy surrounding CME funding, then explains how it tested for bias among its participants. It is important to note that no previously published studies have addressed this perceived bias.
Read more
From Peter Pitts:
Much brouhaha about the DDMAC letter sent to Dr. Leslie Bauman about her enthusiastic comments about a yet-to-be-approved anti wrinkle injectable.
At first blush, this seems like regulatory creep and cause for First Amendment agita. But it isn’t. This is not a case of the FDA trying to stifle unregulated speech by an individual without “interest.” Dr. Bauman is a clinical investigator for the product she’s been touting. That’s “interest” whether the trial sponsor paid her to do so or not. (In this instance, there was no “pay for play.”) In any case, it’s an unambiguous regulatory no-no.
Your comments are welcome here.
The February issue of MM&M magazine spotlights Policymed.com blogger Tom Sullivan.
Recent Comments